What is Brainsgate?
Established in 2000, BrainsGate is at the forefront of developing novel treatments for CNS disorders. The company's proprietary platform technology centers on electrical stimulation of the Spheno-Palatine Ganglion (SPG) to enhance cerebral blood flow. This innovative approach targets debilitating conditions such as ischemic stroke, a primary cause of long-term disability. BrainsGate's commitment to advancing medical solutions offers new hope to patients facing severe neurological challenges.
How much funding has Brainsgate raised?
Brainsgate has raised a total of $40M across 2 funding rounds:
Unspecified
$26M
Private Equity
$14M
Unspecified (2015): $26M with participation from Elron Electronic Industries
Private Equity (2020): $14M led by Cipio, Agate Inc, Elron Electronic Industries Ltd., Spero Health Inc, BNP Paribas, Pitango Venture Capital, and Medtronic plc
Key Investors in Brainsgate
Elron Electronic Industries
Elron Electronic Industries is a foundational Israeli technology holding company with a broad investment focus, including medical technology. Their involvement suggests a strategic interest in BrainsGate's innovative CNS therapies and potential for significant growth.
BNP Paribas
BNP Paribas is a leading global financial institution providing a wide range of banking and investment services. Their participation indicates confidence in BrainsGate's market potential and financial viability, likely supporting the company's expansion efforts.
Pitango Venture Capital
Pitango Venture Capital is a prominent venture capital firm that supports visionary entrepreneurs and groundbreaking companies, with a focus on technology and health sectors. Their investment in BrainsGate highlights the company's innovative approach to neuro-medical devices.
What's next for Brainsgate?
The recent major strategic investment signifies a pivotal moment for BrainsGate, positioning the company for accelerated scaling and market expansion. This capital will likely fuel further research and development, clinical trials, and the commercialization of its SPG stimulation technology. The company's focus on addressing unmet needs in CNS disease treatment, particularly stroke, suggests a strategic roadmap aimed at capturing a significant share of the neuro-medical device market. Future growth will depend on successful clinical outcomes and regulatory approvals, potentially leading to further rounds of financing or strategic partnerships.
See full Brainsgate company page
